

## OESO Newsletter – September 2023

Message to the members of OESO,  
and to all those who have interest in Esophagology



### The **OESO-SEMPIRE** **VIRTUAL EDUCATIONAL CHANNEL** **29th meeting**

From the Medical College of Wisconsin, Milwaukee, WI

Hosted by Nikki **Johnston**, Ph.D.

Professor of Otolaryngology and Communication Sciences

Microbiology and Immunology

Director of Airway, Digestive and Voice Research

### **Thursday, September 28, 2023**

- **Milwaukee, WI** | CST time: 7 – 9 am
- **Europe CET:**
  - Paris: 2 – 4 pm
  - UK: 1 – 3 pm
- **North America:**
  - West Coast: 5 – 7 am
  - East Coast: 8 – 10 am
- **South America:**
  - São Paulo: 9 – 11 am
  - Buenos Aires: 9 – 11 am
- **Africa:**
  - Bomet, Kenya, 3 – 5 pm
- **Asia:** Malaysia, Kuala Lumpur: 8 – 10 pm  
Beijing: 8 – 10 pm
- **Australia:**
  - Melbourne: 10 pm – 12 midnight

- Zoom technology applied

**Registration is free, but mandatory:**

Free registration



## PPI refractory GERD: Perspectives from GI, Surgery, and Research

### Ongoing research:

- **Simon Blaine-Sauer, M.D.** student, Class of 2025  
Medical College of Wisconsin

*Our group and collaborators have identified the protease inhibitor amprenavir and its prodrug fosamprenavir as potent inhibitors of pepsin and a potential therapy against reflux-associated disease, both in the laryngopharynx and the esophagus.*

*Recently, employing an in vitro model using Barrett's esophagus-derived cells, we showed that amprenavir protects against pepsin-induced epithelial barrier disruption and cancer-associated changes.*

*These promising preclinical data, alongside our ongoing parallel studies in the laryngopharynx, support the development of a clinical trial to investigate the efficacy of fosamprenavir for treating PPI-recalcitrant GERD.*

## GIST OF THE CASE

### Presenter:

Dave **Richards**  
Assistant Professor of Medicine  
MD Anderson Cancer Center, Houston, TX

A 59 year old man with right tonsillar fossa squamous cell carcinoma status post chemo/radiation completed 2012, currently NED.

He had presented with progressive dysphagia and found to have an esophageal stricture now s/p dilation.

Past medical history is significant for obstructive sleep apnea and chronic kidney disease.

He has dysphagia, reflux, and aspiration significant enough to require hospitalization and antibiotics.

Reflux is refractory to PPI and pH Impedance study showed normal acid exposure, but he has a heterogenous group of symptoms, including cough, that seemed to be linked to acid reflux episodes, more so than weakly acid or non-acid episodes.

- Is the oropharyngeal function the cause of the aspiration?
- Is it reflux?
- Non-acid reflux now on PPI?



**1** epiglottis, radiation changes



**2** Gastroesophageal Junction

*Gastroesophageal reflux disease significantly impacts patient quality of life and is a major risk factor for the development of Barrett's esophagus and esophageal adenocarcinoma. PPIs are the standard-of-care for GERD and are among the most prescribed drugs in the world. While PPIs are highly effective for resolving erosive lesions due to GERD, they provide insufficient symptom relief in 20–40% of patients with esophagitis and perform even poorer in patients with non-erosive reflux disease.*

**Panel for discussion:**

- Nikki **Johnston** (Medical College of Wisconsin, Milwaukee, WI)
- Simon **Blaine-Sauer** (Medical College of Wisconsin)
- David **Richards** (MD Anderson, TX)
- Sumeet **Mittal** (Norton Thoracic Institute, Phoenix, AZ)

The panel will discuss PPI refractory GERD from a gastroenterology, surgery, and research perspective.



*Thirty Pilot Centers worldwide are currently listed in the network of the OESO-SEMPIRE Platform of Excellence in Esophagology to take part in the program of the **OESO Virtual Educational Channel in Esophagology**. Such a program is in line with true multi-disciplinarity, the essence of OESO since its creation, and the mission defined by UNESCO in the **Chair of Digital Education** attributed in 2018, at the University of Geneva, to the OESO Foundation*



The previous "Staff meeting discussions" were organized in

- **2020:** May 28 (Pilot Center of Milan), July 22 (Pilot Center of Stanford), October 3 (Pilot Center of Bomet, Kenya), October 29 (Pilot Center of Beijing), December 10 (Pilot Center of Geneva),
- **2021:** January 29 (Pilot Center of Melbourne), February 25 (Pilot Center of Bordeaux), March 19 (Pilot Center of Stanford), April 15 (Pilot Center of Paris), May 26 (Pilot Center of Milan), June 23 (Pilot Center of Sao Paulo), August 21 (Asian Pacific Digestive Week), October 19 (Pilot Center of Mainz), November 22 (Pilot Center of Bordeaux), December 9 (Pilot Center of Geneva),
- **2022:** January 20 (Pilot Center of Kota Bharu), February 22 (Pilot Centers of Beijing, Shanghai and Guangzhou), March 24 (Pilot Center of Boston), May 4 (Pilot Centers of Melbourne and Kenya), July 19 (Pilot Center of Kota Bharu), September 23 (Pilot Center of Milwaukee, Wisconsin), October 8 (Pilot Center of Chile), December 14 (Pilot Center of Geneva),
- **2023:** January 11 (Pilot Center of Stanford), February 26 (Pilot Center of Malaysia), March 23 (Pilot Center of Boston), May 24 (Pilot Center of Paris) and June 1 (Pilot Center of Chile).



- **Wherever you are in the world,**
- **Whatever your specialty,**
- **Whatever your level,**

the 29th clinical case of the OESO-SEMPIRE Platform will afford you the opportunity to participate in a global multidisciplinary staff meeting dedicated to one challenging topic of esophagology. It will involve specialists in various disciplines, and participants from any country can connect to the discussions.

Looking forward to seeing you soon!

**Robert Giuli, MD, FACS**  
Professor of Surgery  
Founder & Deputy Executive Director of OESO

The next 30th Clinical case coming up for discussion will be presented in October 2023.

*Details and time will be announced on the OESO website and in the next Newsletter.*

OESO Head Office  
2, Bd Pershing  
75017 Paris, France  
Tel. + 33 (0)1 55 37 90 15  
email: [michele.liegeon@oeso.org](mailto:michele.liegeon@oeso.org)  
[www.oeso.org](http://www.oeso.org)



OESO will not supply your Personal Data to any third party for marketing purposes, whether directly or indirectly.

This email has been sent to [nicole.schranz@architecturevisualdesign.ch](mailto:nicole.schranz@architecturevisualdesign.ch)  
You received this email because you are registered by OESO.

[Unsubscribe](#)



© 2023 OESO

[Show in browser](#)